Extra energy for hearts with a genetic defect: ENERGY trial

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Aims: Previous studies have shown that hypertrophic cardiomyopathy mutation carriers have a decreased myocardial energy efficiency, which is thought to play a key role in the pathomechanism of hypertrophic cardiomyopathy (HCM). The ENERGY trial aims to determine whether metabolic drugs correct decreased myocardial energy efficiency in HCM mutation carriers at an early disease stage. Methods: 40 genotype-positive, phenotype-negative MYH7 mutation carriers will be treated for two months with trimetazidine or placebo in a double-blind randomised study design. Directly before and after treatment, study subjects will undergo an [ 11 C]-acetate positron emission tomography/computed tomography (PET/CT) and cardiac magnetic resonance (CMR) scan to measure myocardial energy efficiency. Myocardial efficiency will be calculated as the amount of oxygen the heart consumes to perform work. Conclusion: The ENERGY trial will be the first proof of concept study to determine whether metabolic drugs are a potential preventive therapy for HCM. Given that trimetazidine is already being used in clinical practice, there is large potential to swiftly implement this drug in HCM therapy.
Original languageEnglish
Pages (from-to)200-205
JournalNetherlands Heart Journal
Volume27
Issue number4
DOIs
Publication statusPublished - 2019

Cite this

@article{115a759d0c3f4d40bb3e5380b53a42ef,
title = "Extra energy for hearts with a genetic defect: ENERGY trial",
abstract = "Aims: Previous studies have shown that hypertrophic cardiomyopathy mutation carriers have a decreased myocardial energy efficiency, which is thought to play a key role in the pathomechanism of hypertrophic cardiomyopathy (HCM). The ENERGY trial aims to determine whether metabolic drugs correct decreased myocardial energy efficiency in HCM mutation carriers at an early disease stage. Methods: 40 genotype-positive, phenotype-negative MYH7 mutation carriers will be treated for two months with trimetazidine or placebo in a double-blind randomised study design. Directly before and after treatment, study subjects will undergo an [ 11 C]-acetate positron emission tomography/computed tomography (PET/CT) and cardiac magnetic resonance (CMR) scan to measure myocardial energy efficiency. Myocardial efficiency will be calculated as the amount of oxygen the heart consumes to perform work. Conclusion: The ENERGY trial will be the first proof of concept study to determine whether metabolic drugs are a potential preventive therapy for HCM. Given that trimetazidine is already being used in clinical practice, there is large potential to swiftly implement this drug in HCM therapy.",
author = "{van Driel}, {B. O.} and {van Rossum}, {A. C.} and M. Michels and R. Huurman and {van der Velden}, J.",
year = "2019",
doi = "10.1007/s12471-019-1239-0",
language = "English",
volume = "27",
pages = "200--205",
journal = "Netherlands Heart Journal",
issn = "1568-5888",
publisher = "Bohn Stafleu van Loghum",
number = "4",

}

Extra energy for hearts with a genetic defect: ENERGY trial. / van Driel, B. O.; van Rossum, A. C.; Michels, M.; Huurman, R.; van der Velden, J.

In: Netherlands Heart Journal, Vol. 27, No. 4, 2019, p. 200-205.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Extra energy for hearts with a genetic defect: ENERGY trial

AU - van Driel, B. O.

AU - van Rossum, A. C.

AU - Michels, M.

AU - Huurman, R.

AU - van der Velden, J.

PY - 2019

Y1 - 2019

N2 - Aims: Previous studies have shown that hypertrophic cardiomyopathy mutation carriers have a decreased myocardial energy efficiency, which is thought to play a key role in the pathomechanism of hypertrophic cardiomyopathy (HCM). The ENERGY trial aims to determine whether metabolic drugs correct decreased myocardial energy efficiency in HCM mutation carriers at an early disease stage. Methods: 40 genotype-positive, phenotype-negative MYH7 mutation carriers will be treated for two months with trimetazidine or placebo in a double-blind randomised study design. Directly before and after treatment, study subjects will undergo an [ 11 C]-acetate positron emission tomography/computed tomography (PET/CT) and cardiac magnetic resonance (CMR) scan to measure myocardial energy efficiency. Myocardial efficiency will be calculated as the amount of oxygen the heart consumes to perform work. Conclusion: The ENERGY trial will be the first proof of concept study to determine whether metabolic drugs are a potential preventive therapy for HCM. Given that trimetazidine is already being used in clinical practice, there is large potential to swiftly implement this drug in HCM therapy.

AB - Aims: Previous studies have shown that hypertrophic cardiomyopathy mutation carriers have a decreased myocardial energy efficiency, which is thought to play a key role in the pathomechanism of hypertrophic cardiomyopathy (HCM). The ENERGY trial aims to determine whether metabolic drugs correct decreased myocardial energy efficiency in HCM mutation carriers at an early disease stage. Methods: 40 genotype-positive, phenotype-negative MYH7 mutation carriers will be treated for two months with trimetazidine or placebo in a double-blind randomised study design. Directly before and after treatment, study subjects will undergo an [ 11 C]-acetate positron emission tomography/computed tomography (PET/CT) and cardiac magnetic resonance (CMR) scan to measure myocardial energy efficiency. Myocardial efficiency will be calculated as the amount of oxygen the heart consumes to perform work. Conclusion: The ENERGY trial will be the first proof of concept study to determine whether metabolic drugs are a potential preventive therapy for HCM. Given that trimetazidine is already being used in clinical practice, there is large potential to swiftly implement this drug in HCM therapy.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063607118&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30767167

U2 - 10.1007/s12471-019-1239-0

DO - 10.1007/s12471-019-1239-0

M3 - Article

VL - 27

SP - 200

EP - 205

JO - Netherlands Heart Journal

JF - Netherlands Heart Journal

SN - 1568-5888

IS - 4

ER -